Bayer and Janssen report positive heart disease data for Xarelto

Bayer and Janssen have announced new clinical trial data showing benefits their novel oral anticoagulant Xarelto can offer in the treatment of cardiovascular disease.

Data from the phase III trial COMPASS – the largest clinical study of Xarelto to date – have shown the efficacy and safety of the drug in preventing major adverse cardiac events including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD).

In doing so, the drug met its primary endpoint ahead of time, with an interim analysis conducted by an independent data monitoring committee leading to a recommendation that the trial be stopped early.

The magnitude of the positive benefits and the confirmation of Xarelto's existing safety profile means the therapy will now be made available to all study participants in an open-label extension trial.

Dr Joerg Moeller, member of the executive committee of Bayer's pharmaceutical division and head of development, said: "We are excited about these results and look forward to making rivaroxaban available to patients with CAD and PAD to reduce their risk of major adverse cardiac events."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.